CD Bioparticles launches specialized RNA Synthesis services for researchers to develop next-generation mRNA vaccines, gene therapies, and RNA-based therapeutics.

Ottawa, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The global RNA therapeutics and vaccines market size is calculated at USD 0.38 billion in 2025 and is expected to reach around USD 107.7 billion by 2034, ...

(MENAFN- GlobeNewsWire - Nasdaq) The global RNA therapeutics and vaccines market size was valued at USD 0.21 billion in 2024 and is predicted to hit around USD 107.7 billion by 2034, rising at a 87% ...

As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.

According to Precedence Research, the global RNA analysis market size is expected to be worth USD 23.39 billion by 2035, increasing from USD 10.21 billion in 2026, with a strong CAGR of 9.65% from ...

From vaccines and diagnostics to emerging gene-based therapies, RNA molecules are now central to modern medicine. But as ...

－実験室での生命誕生過程の再現に向けて－ 理化学研究所（理研）生命機能科学研究センター高機能生体分子開発チームの李佩瑩（リ・ペエイ）研究員、田上俊輔チームリーダーらの国際共同研究チームは、正電荷を持つペプチド[1] 凝集体がRNA[2] を吸着し ...

Researchers developed C28, an engineered polymerase that efficiently synthesizes RNA at near-natural speeds with high accuracy. Created through directed evolution, the enzyme also performs reverse ...

The American pharmaceutical company Moderna announced that the United States Food and Drug Administration (FDA) has refused ...

People are still debating whether the mRNA from COVID-19 vaccines remains in the body longer than it should. Some say it lingers and causes harm, others say that idea just doesn’t hold up. A new ...